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Abstract 
Background: Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) of parkinson’s disease (PD) patients has 
demonstrated to improve motor performance and to reduce dopa-induced dyskinesia. An association between the 
occurrence of dyskinesias and LRRK2 (leucine-rich repeat kinase 2) G2019S gene mutations has recently been sug-
gested. The aim of this study is to discover the impact of the G2019S mutation (with high incidence in the authors’ 
native Algeria) on the symptom response of PD in patients who underwent STN-DBS.
Methods: We carried out a comparative statistical study for the clinical evaluation and neuropsychological assess-
ment of 27 Algerian PD STN-DBS patients, both G2019S mutation carriers (MC) and non-carriers (NC). A multiple cor-
respondence analysis (MCA) was then conducted to compare the results with those from groups of individuals with 
similar modalities.
Results: The MCA revealed that MC and NC PD patients showed two different patterns of clinical evaluations. The 
group of idiopathic patients showed some differences compared to the clinical evaluations, depending on gender. 
No association was found between the G2019S mutation and the Mini Mental State Examination scores (MMSE), and 
MC patients appeared more susceptible to dyskinesia than NC patients. In NC patients, we found two cases with Par-
kin mutations who had a different “honeymoon” period and different initial symptoms. The results showed consider-
able improvement of motor unified parkinson’s disease rating scale III (UPDRS-III) in a situation of stimulation without 
medication in the MC patients with a percentage of improvement (51.1 %) over the required 30 % compared to the 
NC patients (25.5 %). The same result was observed for the Schwab and England’s activities of daily living scale (S 
and E scale), which thus demonstrated a greater effectiveness of DBS for MC patients than for NC patients. However, 
the Hoehn and Yahr scale (H and Y Scale) showed the same significance in a situation of stimulation for MC and NC 
patients. In this later group, the best scores of UPDRS-III were observed for patients with the Parkin mutation before 
they underwent surgery.
Conclusions: This study shows that surgical treatment probably has a more significant impact on LRRK2 G2019S MC 
than on idiopathic patients.
© 2016 Sayad et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Parkinson’s disease (PD) is considered to be a multifac-
torial etiology disease, and, in most cases, the result of 
multiple factor effects, either genetic or environmental. 
Genetic susceptibility factors have also been implicated 
in idiopathic forms of PD. Two independent studies [1, 
2] have identified a mutation in the LRRK2 gene that 
encodes a protein called dardarin. So far, seven validated 
missense mutations have been reported in European and 
North American PD populations. A common G2019S 
mutation was found to account for approximately 5  % 
of familial cases, but for markedly more cases in North 
African (≈40  %) and Jewish populations [3, 4]. In a 
large Algerian PD cohort, a comparative study of clini-
cal aspects and progressive parkinsonian signs between 
G2019S MC and NC patients showed that this mutation 
is probably associated with the occurrence of dyskinesias, 
suggesting a genetic predisposition for these complica-
tions [5].
Although these dyskinesias are difficult to treat, DBS 
has shown to be effective, probably by the removal of 
abnormal action potential profiles [6]. Currently, DBS 
of the STN is regarded as the best surgical treatment for 
L-dopa-responsive symptoms of PD at the stage of motor 
fluctuations [7, 8]. However, with the progression of the 
disease, and despite initial improvement, the response of 
the axial symptoms to L-dopa and therefore to the STN 
stimulation deteriorates progressively [9, 10].
The DBS indication follows CAPSIT-PD recom-
mendations (Core Assessment Program for Surgical 
Interventionnal Therapies in PD) [11], which addition-
ally recommends a disease duration of a minimum of 
5  years and a good sensitivity to L-dopa. There does 
not appear to be a genetic test to determine the crite-
ria for inclusion or exclusion of patients suffering from 
PD and DBS, whereas the share of the G2019S muta-
tion, given its frequent occurrence in our country, in 
the earliest occurrence of dyskinesias and the progres-
sion of the disease may be essential to be able to predict 
the long-term effectiveness of DBS treatment. To do 
this, we have opted for a MCA, which is a multivari-
ate analysis that allowed us to graphically analyze and 
describe remarkable combinations between the genetic 
and clinical parameters of different PD patients having 
undergone DBS.
Methods
This study focused on 27 PD patients who underwent 
bilateral STN-DBS and parameter conditions were tested 
under simple blind randomized conditions.
Each PD patients was implanted at the neurosurgi-
cal department in which he was followed (Salim Zemirli 
Hospital of Algiers, the Mohamed-Seghir Nekkache Mili-
tary Hospital of Algiers and Frantz Fanon Hospital of 
Blida) from April 2006 to October 2012.
The follow-up of the patients was relayed to specialized 
neurosurgeons, neurologists and psychologists in their 
relevant fields of expertise at their respective hospitals 
and at the Neurology department of Ben Aknoun Hos-
pital. The raters did not know the patients’ genetic status 
either before or after surgery.
All PD patients accepted and gave informed consent to 
take part in this anonymous study. For each patient, we 
completed a questionnaire with demographic data such 
as gender, date of birth and profession.
STN‑DBS surgical procedure
The CAPSIT-PD recommendations for STN-DBS were 
followed in all patients for the three neurosurgical 
departments. The most important criteria for STN-DBS 
eligibility are: patients with correct diagnosis of idio-
pathic PD with age at surgery <60 years, good sensitivity 
to L-dopa with presence of dyskinesias.
The same surgical technique and equipment for the 
bilateral implantation was used for all patients. Coor-
dinates of the targets were defined by imaging methods 
such as computerized tomography scans (CT-scan) and 
magnetic resonance imaging (MRI). The location of the 
leads was checked at the end of surgery by bidirectional 
skull X-ray in the stereotactic frame. Each contact of 
the lead was tested in monopolar mode at a predefined 
pulse width (typically 60 μs for most DBS devices) and 
frequency (typically 130  Hz) and the amplitude was 
increased carefully until the first stimulation-induced 
adverse effect appeared. Conversely, if the electrode 
had not been well placed, the neurologist was able to 
test different combinations, including bipolar settings. 
The stabilization period was dedicated to the gradual 
adjustment of stimulation parameters and medication. 
It tended to be completed within 3–6  months after 
surgery.
Keywords: Subthalamic Nucleus Deep Brain Stimulation (STN-DBS), Parkinson’s disease (PD), LRRK2 (Leucine-rich 
repeat kinase 2) G2019S gene mutations, Mutation carrier (MC), Non-carriers (NC), Multiple correspondence analysis 
(MCA), Mini Mental State Examination (MMSE), Unified parkinson’s disease rating scale III (UPDRS-III), Schwab and 
England’s activities of daily living scale (S and E scale), Hoehn and Yahr scale (H and Y scale)
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In this study, we report surgery-related complications 
occurring after STN-DBS.
Clinical study
We prepared a form that was filled in by the neurologist 
and that recorded the clinical forms of the disease, age and 
clinical signs from the onset, as well as treatment, the hon-
eymoon period, progression of the disease, DBS duration, 
Unified Parkinson’s Disease Rating Scale III (UPDRS-III), 
Hoehn and Yahr stage (H and Y stage), Schwab and Eng-
land quality of life scale (S and E scale) in four medication 
situations and DBS as medication-stimulation Off–Off 
(before surgery, at least 12 h after the last dose of L-dopa), 
On–Off (before surgery, at 1 h after the administration of 
L-dopa), Off–On (at least 12 h after the last dose of L-dopa 
and 1 h after the stimulator was turned on) and On–On 
(24 months postoperatively, at 1 h after the administration 
of L-dopa and 1 h after the stimulator was turned on) in 
the same time intervals for all patients. The UPDRS-III is 
more suitable for motor evaluation. It is used to quantify 
therapeutic improvement and progression of the disease. 
The H and Y stage allows having a global vision of the dis-
ease while S and E scales enable the rating of the degree of 
autonomy of PD patients [12].
The so-called “honeymoon period” corresponds to the 
period of improved survival, when PD patients are most 
responsive to L-dopa and ends when treatment-associ-
ated complications such as dyskinesias start.
Neuropsychological assessment
The Mini Mental State Examination (MMSE) evaluates 
memory and orientation in time and space, attention and 
basic arithmetic functions, memory retention, language 
and constructive praxis.
Screening of the LRRK2 G2019S, Parkin, Pink1 and DJ‑1 
mutations
Blood samples were collected and family trees were made 
for each patient. We took care to mention the family 
history of the disease, the number of deceased relatives 
who had suffered from PD (Lohman) and the presence or 
absence of consanguinity.
DNA was extracted with the phenol/chloroform tech-
nique and then stored at −20 °C until use.
The G2019S mutation in exon 41 of the LRRK2 gene 
(rs34637584) results in a change from a guanine (GGC) 
to an adenine base (AGC) at codon which changes a gly-
cine to a serine at position 2019.
Also, we analyzed the recessive genes (Parkin, Pink1 
and DJ-1) for NC patients with linkage study. This study 
was performed by analyzing of microsatellite located in or 
near gene then by sequencing of individuals having all of 
the microsatellite markers homozygous. The thermocycler 
used was BIO-RAD (DNA Engine, Peltier Therma Cycler). 
We screened all 12 exons for Parkin mutations, 8 exons 
for PINK1 mutations (Exon 1 was tested in two overlap-
ping parts 1a and 1b) and 7 exons for DJ1 mutations.
The genotyping was performed in the Brain and Spi-
nal Cord Institute of Paris (France) for all patients. We 
used the TaqMan assay (Applied Biosystems™ kit) on 
the Applied Biosystem 3739 DNA Analyzer sequencer 
(HITACHI). Any changes were checked by sequencing 
using the SeqScape v2.6 software.
Statistical analysis
The Friedman’s two-way analysis of variance (ANOVA) 
by ranks was performed as test of comparisons in paired 
sample populations subjected to four different situations 
of medication and stimulation.
MCA is a multivariate analysis based on measurements 
of several variables with two or more modalities. The 
expected links were highlighted by analyzing and graphi-
cally descriptions, on a graph with the two maximal 
variance factors, the groups of individuals with similar 
modalities. The interpretation of MCA is generally based 
on parameters showing the best qualities of representa-
tion (cos2 factor). Means are shown as x± SD (SD is the 
standard deviation).
Results
The 27 Parkinsonian patients (17 males and 10 females 
(sex ratio 1.70)), who underwent DBS at STN level, had 
an average age of 55.4 ± 8.0 years and an average age at 
the onset of the disease of 40.2 ± 8.7 years. There were 
no significant differences between males and females 
with respect to age at time of examination and age at 
onset (Table 1).
Age groups and gender
The link between the age groups and gender was slightly 
significant (χ2 = 6.15, p = 0.046), with men predominat-
ing in the highest age groups (60–70 years), and women 
in the intermediate age groups (50–60  years). This was 
highlighted and confirmed by the MCA (Fig. 1a).
Age at examination and age at onset of PD
There was no connection between age at onset and 
presence of the G2019S mutation (χ2 = 0.90, p = 0.34). 
However, there was a tendency towards a link between 
so-called honeymoon period (up to 5  years and more 
than 5 years) and the presence of the mutation (χ2 = 4.30, 
p =  0.04  <  0.05), there were significantly more G2019S 
MC patients with shorter honeymoon period than the 
NC patients. The results also showed that 70.4 % of the 
patients had a honeymoon period shorter than 5  years 
when taking L-dopa.
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Psychological assessment
The χ2 test was not significant (p = 0.60 ≫ 0.05), so there 
was no significant difference of MMSE score between the 
G2019S MC and NC patients (25.3 ± 3.1 and 26.2 ± 2.7 
respectively) (Table 2).
In our series, 74.1 % had a normal MMSE (25–30). In 
the remaining 25.9  %, there were five female and two 
male patients with a low sociocultural level and one 
patient with aphasia.
Lead location and DBS complications
Of the 54 contacts used for bilateral STN-DBS (for 27 
patients), 53 contacts were localized in or near the STN. 
We registered one contact in the right side of brain to be 
localized outside of the STN. In three cases, we encoun-
tered DBS complications (one MC patient and two NM 
patients) with moderate pneumocephalus in the frontal 
region and three other cases (one MC patient and two 
NM patients) had stimulator infections.
Comparative evaluations of the optimal stimula-
tion parameters are: pulse width 60  μs, frequency 
130  Hz, amplitude means are 2.32 ±  0.50  V at left and 
2.35 ± 0.54 V at right side STN.
Genetic study
The genetic study revealed the presence of the G2019S 
mutation in 55.6  % of PD patients who had under-
gone DBS stimulation with an average age at examina-
tion of 56.2 ± 8.8 years and an average age at the onset 
of the disease of 40.1 ±  9.4 years. The NC patients had 
the same average age at examination and average age at 
onset (54.5 ± 7.1 and 40.3 ± 8.2 years respectively). The 
average duration of the honeymoon period (period dur-
ing which there is a sustained response to dopaminergic 
treatment and the patient does not have a dyskinesia) was 
slightly shorter in patients with the MC (3.8 ± 1.7 years) 
than those with NC (5.4 ± 2.6 years) (Table 2).
Among all the NC patients, we found only two cases 
(16.66 %) of Parkin mutation (heterozygous c. 1204C>T 
in exon 11 and c. 458C>G in exon 4) with an age at onset 
of PD of 48 years, different initial symptoms and duration 
honeymoon (Table 3).
Clinical UPDRS‑III, S and E scales and H and Y stages
The UPDRS-III of MC patients in Off–Off medica-
tion-stimulation situations had an average score of 
55.8  ±  16.4, which was significantly higher than the 
scores in three other cases (average score <28; Table 4). 
Table 1 Clinical characteristics of 27 STN-DBS patients in relation to gender
PD parkinson’s disease, STN subthalamic nucleus, Min minimum, Max maximum
Means Min Max Men (n = 17) Women (n = 10) p
Age groups (years) 55.4 ± 8.0 41 69 56.4 ± 9.5 53.8 ± 4.3 0.34
Age at onset of PD (years) 40.2 ± 8.7 25 55 40.9 ± 10.7 39.0 ± 3.9 0.34
Duration of disease (years) 15.3 ± 3.0 10 20 15.5 ± 3.3 14.9 ± 2.5 0.60
Duration of honeymoon (years) 4.5 ± 2.3 0.25 10 4.5 ± 1.8 4.6 ± 3.0 0.91
Duration of STN-stimulation (years) 4.7 ± 1.4 2.6 8 4.9 ± 1.5 4.2 ± 1.2 0.18
Fig. 1 Multiple correspondence analysis (MCA) between clinical 
and genetic variables. a On the left side: MC mutation carriers, NC 
non-carriers, Age: age classes (years), Onset.PD: Age at onset of PD 
(years), Dur.Dis duration of disease (years), Treat Treatment (Treat 
1 <=500 mg/day, Treat 2 > 500 mg/day), DBS duration of deep brain 
Stimulation (years), HoneyM duration of honeymoon (years). b On 
the right side: MC mutation carriers, NC non-carriers, F.Backg family 
background of the disease, Wors Worsening (Q quick, S slow), Inbr 
inbreeding, asymmetry: As(R) right asymmetry, As(L) left asymmetry, 
disease form: Mix.F mixed form, Akin.F akinetic rigid form, Lohman: 
Loh0, Loh1, Loh2, several deaths. The green, orange and red colors 
were respectively for high, intermediate and high modalities of the 
variables
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Indeed, the mean values of UPDR-III decreased from 
55.8  ±  16.4 (in Off–Off situation) to 27.3  ±  20.6 (in 
Off–On medication-stimulation), therefore, this is an 
UPDRS-III improvement of 51.1 % compared to the value 
Off–Off (very highly significant p = 0.000046 ≪ 0.001).
For NC patients, the test was very highly significant too 
(p < 0.001). The UPDRS-III in Off–Off medication-stim-
ulation had an average score of 51.7  ±  14.4 again, and 
was significantly higher than the other three situations 
(average score <39) (Table 4). The mean values of UPDR-
III decreased by 51.7  ±  14.4 (in Off–Off situations) to 
38.5  ±  16.6 (in Off–On medication-stimulation situa-
tions). So, this is an UPDRS-III improvement of 25.5  % 
(non significant p = 0.09). The best scores of UPDRS-III 
of Parkin mutation patients were observed in a situation 
of medication (On–Off situation) compared with a post-
operative situation (Table 3).
The comparison of the four UPDRS-III situations 
showed more significance in MC patients (Fridman’s 
ANOVA p  =  0.00005  ≪  0.001)  than in NC patients 
(p = 0.0003) (Table 4).
Similar results were found for the four S and E scale sit-
uations, which showed more significant variations in MC 
patients (p = 0.00001 ≪ 0.001) compared to NC patients 
(p = 0.001) (Table 4). The S and E scale for MC patients 
in Off–On medication-stimulation had an average score 
of 0.6 ±  0.21, while the Off–Off situation had the low-
est at 0.43 ± 0.18 (slightly significant p = 0.036). Similar 
results were found for the NC patients, with an average 
score of 0.6 ± 0.26 for the Off–On medication-stimula-
tion, while the lowest was at 0.53 ± 0.14 for the Off–Off 
(non significant p = 0.41).
The comparison of the four H and Y stage situations 
showed more significance variations in MC patients 
(p  =  0.00002  ≪  0.001) compared to NC patients 
Table 2 Clinical comparative study of 27 STN-DBS patients 
in relation with presence/absence of G2019S mutations
PD parkinson’s disease, MMSE Mini Mental State Examination, STN subthalamic 
nucleus, MC mutation carriers, NC non mutation carriers
MC (n = 15) NC (n = 12) p
Age groups (years) 56.2 ± 8.8 54.5 ± 7.1 0.59
Age at onset of PD (years) 40.1 ± 9.4 40.3 ± 8.2 0.97
Duration of disease (years) 16.1 ± 3.0 14.3 ± 2.7 0.10
MMSE (maximum score 30) 25.3 ± 3.1 26.2 ± 2.7 0.60
Duration of honeymoon (years) 3.8 ± 1.7 5.4 ± 2.6 0.08
Duration of STN-stimulation (years) 5.1 ± 1.4 4.1 ± 1.3 0.09
Table 3 Case reports of patients with Parkin mutation
Case 1 Case 2
Gene and Parkin Parkin
Exon with mutation Exon 4 Exon 11
Mutation type Heterozygous Heterozygous
c. 458C>G c. 1204C>T
Protein change P153R p. Arg402Cys
Gender Male Male
Age at onset 48 years 48 years
Disease duration 10 years 13 years
Family history of Parkinson-
ism
Negative Negative
UPDRS-III Off–Off scores 46/108 49/108
UPDR-III On–Off scores 28/108 32/108
UPDRS-III Off–On scores 51/108 51/108
UPDRS-III On–On scores 30/108 47/108
Initial symptoms Resting tremor in left 
hand, dyskinesias 
4 years after initiation  
of treatment.
Muscle stiffness 
in both upper 
limbs, dyskinesias 
7 years after 
initiation of treat-
ment.
Table 4 Clinical UPDRS-III, S and  E scales and  H and  Y stages scores of  PD MC and  NC patients undergoing STN-DBS 
(mean ± SD)
Unified parkinson’s disease rating scale III (UPDRS-III); Hoehn and Yahr scale (H and Y scale); Schwab and England’s activities of daily living scale (S and E scale)
MC mutation carriers, NC non mutation carriers
Medication stimulation UPDRS‑III S and E scale H and Y scale
situations MC NC MC NC MC NC
Off–Off 55.8 ± 16.4 51.7 ± 14.4 0.43 ± 0.18 0.52 ± 0.14 3.50 ± 0.86 3.54 ± 0.65
On–Off 25.0 ± 13.2 30.6 ± 16.7 0.70 ± 0.13 0.69 ± 0.16 2.36 ± 0.66 2.87 ± 0.90
Off–On 27.3 ± 20.6 38.5 ± 16.6 0.60 ± 0.21 0.60 ± 0.26 2.36 ± 0.69 2.16 ± 0.91
On–On 19.7 ± 18.8 18.8 ± 12.5 0.85 ± 0.16 0.89 ± 0.10 2.13 ± 0.71 1.91 ± .99
p 0.00005 0.0003 0.00001 0.00106 0.00002 0.00091
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(p = 0.0009) (Table 4). The H and Y scale in the Off–Off 
situation had an average score of 3.50 ± 0.87, which was 
significantly higher than in the three other cases (aver-
age score <2.40). The H and Y stage for MC patients in 
Off–On medication-stimulation had an average score of 
2.36 ± 0.69, while the Off–Off situation had the highest at 
3.50 ± 0.87 (very highly significant p = 0.0003 ≪ 0.001).
For NC patients, the test was very highly significant too 
(p = 0.0009 < 0.001). The H and Y scale in the Off–Off 
situation had an average score of 3.54 ± 0.66, which was 
significantly higher than in the three other cases (aver-
age score <2.90). The H and Y stage for NC patients in 
Off–On medication-stimulation had an average score of 
2.16 ± 0.91, while the Off–Off situation had the highest at 
3.54 ± 0.66 (very highly significant p = 0.00005 ≪ 0.001).
Multiple correspondence analysis (MCA)
Figure 1a shows lower modalities of the variables on the 
left side for men and higher modalities of the variables on 
the right side for women.
The MCA provided added value and shows that NC 
women, who were in the average age groups (50–60 years 
old), had a disease duration of between 14 and 18 years, 
treated with high doses (>500 mg/day).
Conversely, MC men and L-dopa dose was reduced to 
below 500 mg/day after DBS, were in the 60–70 years age 
group and had developed the disease later than women 
(40–55 years old).
The distinction between the two groups (enclosed at 
left side of Fig.  1b) was fairly clear and shows that MC 
patients have no family history of the disease and tended 
to have a mixed form of the disease with right asymme-
try predominance. However, the Clustering in the left 
lower figure is characterized by the presence, in female 
patients, of an akinetic-rigid form of the disease, and a 
family history of the disease with consanguinity.
The third group (on the right side of Fig. 1b) was that 
of the non-G2019S mutation carrying male patients, with 
no consanguinity and rapid worsening of the disease.
Discussion
The average age at onset of the disease was 40.2  ±  8.7 
with 48.1 % in the patients having early onset of the dis-
ease (25–40 years old) and 51.9 % with a disease onset age 
of 40–70 years old. This is in contrast with the literature, 
where PD is rarely observed to occur before 40 years of 
age (early PD onset represents less than 10 % of the cases) 
and 80  % of the cases start between the ages of 40 and 
75 years [13]. This may be explained by the prevalence of 
a common idiopathic form in our series.
There were more males than females in our series, with 
a gender ratio of about 1.7. This difference would be justi-
fied, according to Moisan and Elbaz [14], who reported 
a gender ratio of 1.5 to the more frequent occupational 
exposure of men to neuro-toxic substances, and the 
neuro-protective effect of estrogen or a genetic factor 
linked to the X chromosome on women. Indeed, 70  % 
of the women in our series did not have a profession, 
whereas the men all did, be it manual laborers or white 
collar workers. In our series, female gender was more 
common amongst MC than NC (60 vs. 40 %). Indeed, it 
has been shown that PD patients with LRRK2 mutations 
are more likely to be women, suggesting a high genetic 
load versus idiopathic [15]. In addition, we should not 
exclude the fact that these patients were pre-selected for 
DBS after the processing of their files and that the gender 
criterion did not appear in the selection criteria.
We experienced a few complications with the DBS pro-
cedures. These complications are explained by the dura-
tion of surgery and the numbers of electrode penetration 
[16, 17]. The poor outcome of STN-DBS in PD is gener-
ally related either to incorrect implantation or to hard-
ware failure [18]. Incorrect lead placement, which may be 
due to a number of factors, including stereotactic inac-
curacy, poor initial targeting or loss of cerebrospinal fluid 
during surgery, may have led to brain shift [19].
Monopolar stimulation (amplitude 2.32  ±  0.50  V at 
left and 2.35 ± 0.54 V at right side STN, width 60 μs, fre-
quency 130 Hz) has been used in most patients by most 
studies [20, 21]. Therapeutic amplitudes for DBS nor-
mally range between 1 and 4 V and the pulse width for 
stimulation of STN is 60 μs. Also, the frequency is 130 Hz 
in order to reach maximal benefit with minimal battery 
drain [22].
The presence of the G2019S mutation was observed in 
15 patients (i.e. 55.6 % of the cases), including 8 sporadic 
and 7 familial PD patients, all heterozygous. This num-
ber is higher than the one reported by Belarbi and col-
laborators [5] for the Algerian population; with their 34 
MC patients (i.e. 32.4 %) of which 28 were sporadic and 
6 were familial PD patients. It was heterozygous in the 
familial form and sporadic in almost all cases.
The majority of MC patients had late onset of the dis-
ease (after 40 years old) and a relatively short honeymoon 
period (5  years), while NC patients were mostly found 
to have early onset (between 20 and 40  years old) and 
a longer honeymoon period (between 6 and 10  years). 
According to Belarbi and collaborators [5], the compari-
son of the clinical and evolutionary signs in G2019S MC 
and NC in PD showed a similarity in the clinical signs 
but the motor complications of the treatment induced by 
L-dopa were more frequent for the MC patients. Thus, 
this mutation appeared to be associated with the occur-
rence of dyskinesias given the high frequency of its com-
plications in MC, suggesting a genetic predisposition to 
these complications.
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Two NC patients (16.66  %) showed Parkin muta-
tions, one was an early-onset case (48 years). Indeed, we 
reported in the literature that the Parkin mutation has 
been identified in several families with autosomal reces-
sive early-onset Parkinsonism [23, 24] and frequency has 
been estimated at 10–25  % [25]. In contrast, the clini-
cal characteristics of some European and North African 
patients with Parkin mutations were characterized with 
an age at onset of up to 58  years [24, 26]. The “honey-
moon period” and initial symptoms were different in two 
patients with the Parkin mutations (the heterozygous 
c.1204C>T mutation in exon 11 and c.458C>G mutation 
in exon 4 of Parkin). In the literatures, the roles of Parkin 
heterozygous mutations at risk for PD have not been con-
clusively shown [27, 28]. Nevertheless, in a recent study, a 
disease-associated heterozygous mutation of Parkin was 
found in one patient with early-onset, slowly progres-
sive Parkinson’s disease with Lewy bodies and very late 
development of dementia [29]. However, the number of 
patients with Parkin mutation in our series so far is small 
and the correlations between genotype and phenotype 
are uncertain.
The MCA revealed the presence of some clinical set-
tings common to patients with the LRRK2 G2019S 
mutation compared to NC. The G2019S patients were 
probably characterized by the mixed form of the disease 
with predominance of right side asymmetry.
On the other hand, NC patients may show differ-
ences with respect to certain clinical gender parameters. 
Males with no family consanguinity and in an age group 
between 60 and 70 years possibly developed the disease 
later than females (40–55  years old). At the same time, 
females with family consanguinity and in age group 
between 50 and 60 years old likely developed the disease 
earlier (20–40 years old), with an akineto-rigid form with 
predominance of left side asymmetry.
The literature shows that there is no associated phe-
notype related to MC. Although the clinical evaluation 
resembles that of a typical Parkinsonian syndrome, the 
age of onset of the disease is remarkably variable, ranging 
from 35 to 78  years [4]. Moreover, recent study reveals 
that G2019S MC patients is similar to NC PD patients 
but is characterized with more frequent lower extremity 
involvement at onset and postural instability and gait dif-
ficulty without the associated cognitive impairment [30].
It is also known that during the pathological neurode-
generation process, lesion distribution, initially unbal-
anced, occurs at the same time as the occurrence and 
worsening of clinical symptoms. Thus, this evolution of 
the pathological process can sometimes lead to the domi-
nance of a different subtype of clinical expression of the 
initial diagnosed subtype [31, 32]. A recent neuropatho-
logical study also showed a pleomorphic phenotype in 
this MC [33]. This clinical and pathological variability 
suggests that the G2019S mutation plays a role in several 
neurodegeneration interactions.
No significant difference was observed in MMSE 
between MC patients and NC. In fact, Goldwurm and 
collaborators [34] reported that there were no significant 
cognitive dysfunctions in MC and NC. Lesage and col-
laborators [4] also reported an insignificant difference in 
MMSE in a French and North African population. On the 
other hand, Barth and collaborators [5] reported the low-
est MMSE in MC patients, which the authors attributed 
to the small size of the sample in their study.
The UPDRS-III graphics show a marked improve-
ment in the clinical spectrum of the PD patients. The 
percentage of improvement of 51.1  % for the G2019S 
MC patients in Off–On medication-stimulation situ-
ations was above 30  %. It is empirically considered that 
an improvement of more than 30 % of the UPDRS-III is 
clinically significant [12]. In NC patients, the percentage 
of improvement under stimulation without drug therapy 
was below the required 30 % (25.5 %). The S and E scales 
as well as the H and Y stages in various situations of med-
ication and stimulation also showed a marked improve-
ment during Off–On medication-stimulation. This result 
demonstrates the effectiveness of DBS. It is known that 
DBS at the STN level largely improves the quality of life 
of patients because it acts on all aspects of the PD triad: 
tremor, rigidity and akinesia [35]. According to a study 
dating from 2011, the improvement in UPDRS-III was 
41  % compared with the control group 12  months after 
surgery [36]. The first beneficial effects occur in the min-
utes following the start of the stimulation [35]. In the 
long run, DBS is more stable than L-dopa treatment, and 
motor fluctuations and dyskinesia become minor [37].
However, the differences in the UPDRS-III, the S and 
E scales as well as the H and Y stages in the four situa-
tions for MC patients were more significant than for 
NC patients. Also, the comparison between MC and 
NC in a situation of stimulation and a situation without 
medication-stimulation in the UPDRS-III and the S and 
E scales showed the best response for the MC patients. 
This means that the G2019S MC patients have a better 
response than NC patients. In fact, it is known from the 
literature that patients with LRRK2 mutations are good 
candidates for STN stimulation [38, 39], but limited 
series are available so far. In contrast, other studies sug-
gested that no influence by the LRRK2 G2019S muta-
tion exists on STN-DBS results [38, 40, 41]. However, the 
series reported in the literature are lower than our series 
(15 MC patients). It is supposed that this mutation makes 
PD patients more vulnerable to dyskinesias [5] or to some 
deleterious reorganization of corticostriatal efferents that 
would be modulated by the STN-DBS [39]. This leads us 
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consider that this mutation may have impact on the pro-
gression and response to STN-DBS. Further larger stud-
ies are needed to confirm these findings.
The patients with the Parkin mutation have the best 
UPDRS-III scores in the On–Off medication-stimulation 
situation compared to other situations. According to 
the literatures, the effect of DBS did not differ between 
patients with and without Parkin mutations [42, 43].
Conclusion
In our study, MCA revealed the presence of two distinct 
groups: MC and NC had two different clinical evalua-
tions. The MC patients were probably characterized by 
the mixed form of the disease, with a predominance of 
right side asymmetry. In the NC group, men from non-
consanguineous families and with an age (at examina-
tion) ranging between 60 and 70 years may develop the 
disease later than the women (40–55 years).
Other noteworthy findings were a shorter honeymoon 
period of MC patients compared to the NC. Moreover, in 
the later group, we found two patients with Parkin muta-
tions who had a different honeymoon period and differ-
ent initial symptoms. Also, the results showed that the 
G2019S mutation was not associated with MMSE scores.
Other significant results were a clear improvement in 
the UPDRS-III more for MC than for NC patients who 
underwent stimulation with percentages of improvement 
over the required 30  % for MC patients only (51.1 and 
25.5 % respectively). We found the same result for the S 
and E scales, which thus demonstrated the effectiveness 
of DBS for MC patients more than for NC patients. This 
indicates that, compared to NC patient, MC patients are 
probably the best candidates for STN-DBS. On the other 
hand, the best scores of UPDRS-III observed in  situa-
tions where Parkin mutation patients received medica-
tion suggest that STN-DBS probably did not benefit these 
patients.
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